1519 studies found for:    "Sexually Transmitted Diseases, Viral"
Show Display Options
RSS Create an RSS feed from your search for:
"Sexually Transmitted Diseases, Viral"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Feasibility of Measuring Immune Resp, Activation in Foreskin/Mucosa in HIV-, Uncircumcised High-HIV-risk MSM, Lima Peru
Conditions: HIV Infections;   Acquired Immunodeficiency Syndrome;   Lentivirus Infections;   Retroviridae Infections;   RNA Virus Infections;   Virus Diseases;   Sexually Transmitted Diseases, Viral;   Sexually Transmitted Diseases;   Immunologic Deficiency Syndromes;   Immune System Diseases;   Slow Virus Diseases
Interventions: Procedure: Circumcision;   Procedure: Flexible sigmoidoscopy
2 Completed Measuring Responses to Sublingual Antigens
Condition: Sexually Transmitted Diseases, Viral
Intervention: Biological: Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads
3 Completed Group Therapies for Reducing HIV-risk Behavior in Women Who Have Survived Childhood Sexual Abuse
Conditions: Alcoholism;   Child Abuse, Sexual;   Sexual Abuse;   Sexual Behavior;   Sexually Transmitted Diseases, Viral
Intervention: Behavioral: Trauma-focused group therapy
4 Completed HIV Prevention Intervention for Couples
Condition: Acquired Immunodeficiency Syndrome
Interventions: Behavioral: Couples HIV counseling and testing;   Behavioral: Women's relationship-focused HIV counseling and testing
5 Recruiting Early cART and cART in Combination With Autologous HIV-1 Specific Cytotoxic T Lymphocyte (CTL) Infusion in The Treatment of Acute HIV-1 Infected Adults
Condition: Acute HIV Infection
Interventions: Drug: cART(TDF/AZT+3TC+LPV/r);   Procedure: CTL infusion
6 Completed Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART
Condition: HIV Infection
Intervention: Drug: Panobinostat
7 Terminated The Mochudi Prevention Project ART Protocol
Condition: HIV Infections
Intervention: Drug: highly active antiretroviral therapy: Lopinavir/Ritonavir, Lamivudine, Zidovudine, Efavirenz, Tenofovir Disoproxil Fumarate, Emtricitabine
8 Terminated A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy
Condition: HIV Infections
Interventions: Drug: MPC-4326 plus a 2-3 drug optimized background regimen (OBR);   Drug: 3-4 commercially available antiretroviral drugs
9 Recruiting Clinical Trial of Recombinant Adenovirus Type 5 AIDS Vaccine
Condition: Acquired Immunodeficiency Syndrome
Interventions: Biological: Ad5-gag;   Biological: Placebo
10 Completed Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus
Condition: Hepatitis C, Chronic
Interventions: Drug: Peg-Interferon Alpha-2A;   Drug: Ribavirin
11 Not yet recruiting Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts
Condition: Genital Warts
Interventions: Biological: Quadrivalent HPV vaccine;   Biological: Hepatitis B vaccine
12 Recruiting Using Telmisartan With ART During Acute HIV Infection to Reduce the CNS Reservoirs of HIV and Lymph Node Fibrosis
Conditions: Acute HIV Infection;   HIV CNS Involvement
Interventions: Drug: TDF/3TC/EFV + Telmisartan;   Drug: TDF/3TC/EFV only
13 Not yet recruiting Modulating the Impact of Critical Events in Early HIV Infection: Effect of ART Initiation and Alcohol Use
Condition: HIV Infection
Interventions: Other: ART initiation at time of HIV diagnosis;   Other: ART at 24 weeks post-diagnosis
14 Not yet recruiting Liraglutide for HIV-associated Neurocognitive Disorder
Conditions: HIV Infection;   Diabetes Mellitus Type 2;   Obesity;   Overweight;   Metabolic Syndrome
Intervention: Drug: Liraglutide
15 Not yet recruiting Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: DTG;   Drug: RPV;   Drug: DTG/RPV FDC
16 Not yet recruiting Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults
Conditions: Dengue Fever;   Dengue Hemorrhagic Fever;   Human Immunodeficiency Virus
Interventions: Biological: CYD Dengue Vaccine;   Biological: Placebo (NaCl 0.9%) vaccine group
17 Not yet recruiting Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: Dolutegravir 50 mg tablet;   Drug: Lamivudine 300 mg tablet;   Drug: Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA);   Drug: Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)
18 Recruiting A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)
Conditions: Hepatitis C Virus Infection;   Human Immunodeficiency Virus Infection;   Chronic Hepatitis C;   Compensated Cirrhosis and Non-cirrhotics
Intervention: Drug: ABT-493/ABT-530
19 Completed Efficacy, and Safety Study of Optimized Background Antiretroviral Regimen (OB) in Combination With Enfuvirtide in the Treatment-Experienced Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection
Condition: HIV Infections
Interventions: Drug: Enfuvirtide;   Drug: Optimized background antiretroviral regimen (OB)
20 Completed MMR Vaccination Among HIV-infected Adults
Condition: HIV
Intervention: Biological: 0.5 ml of MMR vaccine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years